Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inclacumab - Global Blood Therapeutics/Roche

Drug Profile

Inclacumab - Global Blood Therapeutics/Roche

Alternative Names: DSM ACC2641; LC1004-002; R 1512; RG1512; RO 4905417

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab; Roche
  • Developer Roche
  • Class Anti-inflammatories; Anti-ischaemics; Monoclonal antibodies
  • Mechanism of Action P selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute coronary syndromes; Myocardial infarction; Peripheral vascular disorders

Most Recent Events

  • 23 Aug 2018 Inclacumab licensed to Global Blood Therapeutics worldwide
  • 23 Aug 2018 Global Blood Therapeutics announces intention to submit Investigational New Drug application to the US FDA for Sickle cell anaemia in 2021
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top